Jefferies Asumes, Upgrades AcelRx Pharmaceuticals (ACRX) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
AcelRx Pharma (ACRX) Posts Suprise Q3 Profit
October 29, 2015 4:05 PM EDTAcelRx Pharma (NASDAQ: ACRX) reported Q3 EPS of $0.01, $0.24 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $13.9 million versus the consensus estimate of $1.75 million.
For earnings history and earnings-related data on AcelRx Pharma (ACRX) click here.
... More